KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Equity Average (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Equity Average data on record, last reported at $1.3 billion in Q3 2025.

  • For Q3 2025, Equity Average rose 16.51% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, up 16.51%, while the annual FY2024 figure was $1.2 billion, 91.84% up from the prior year.
  • Equity Average reached $1.3 billion in Q3 2025 per SRPT's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, Equity Average topped out at $1.4 billion in Q4 2024 and bottomed at $407.9 million in Q4 2022.
  • Average Equity Average over 5 years is $853.9 million, with a median of $791.7 million recorded in 2022.
  • Peak YoY movement for Equity Average: tumbled 53.35% in 2021, then skyrocketed 99.03% in 2023.
  • A 5-year view of Equity Average shows it stood at $698.8 million in 2021, then tumbled by 41.63% to $407.9 million in 2022, then skyrocketed by 99.03% to $811.8 million in 2023, then skyrocketed by 69.29% to $1.4 billion in 2024, then decreased by 2.59% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $1.3 billion in Q3 2025, $1.3 billion in Q2 2025, and $1.3 billion in Q1 2025.